Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Atara Biotherapeutics (ATRA) reported a Q3 loss of $2.93 per share, which was better than the Zacks Consensus Estimate of a $3.77 loss. This is an improvement from the $16.50 loss per share a year ago.
November 12, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atara Biotherapeutics reported a Q3 loss of $2.93 per share, beating the Zacks Consensus Estimate of a $3.77 loss. This marks a significant improvement from the $16.50 loss per share a year ago.
The better-than-expected earnings report and significant improvement from the previous year's loss are likely to positively impact Atara Biotherapeutics' stock price in the short term. Investors may view the reduced loss as a sign of progress.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100